Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05127798 | RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. | unknown | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Nov 19, 2021 |
| clinicaltrials |
| NCT05123352 | Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies | unknown | — | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | unknown | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05017883 | TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04613622 | Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05092048 | A Study for PRO of CML in Real Word(Case-Only) | unknown | — | 10,000 | xunaOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05080829 | Myeloid Mutations Register in R/R CML | unknown | N/A | 29 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04446741 | Molecular Diagnostic Platform for AML | unknown | — | 2,000 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05016752 | Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection | unknown | — | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05000801 | Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia | unknown | N/A | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04991532 | Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells | unknown | — | 324 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04931992 | Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.(MOLAM) | unknown | — | 100 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04906031 | Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations | unknown | Phase 2 | 5 | First Affiliated Hospital of Jinan UniversityOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04920500 | Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients | unknown | N/A | 16 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04069208 | IA14 Induction in Young Acute Myeloid Leukemia | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01894477 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | unknown | Phase 2 | 102 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04904237 | Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | unknown | Phase 2 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | unknown | N/A | 26 | Northwestern UniversityOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04884984 | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03080766 | The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype | unknown | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04818619 | TIGIT in Patients With Chronic Myeloid Leukemia | unknown | — | 65 | Assiut UniversityOTHER | 0 | Mar 29, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01296178 | PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years | unknown | N/A | 200 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT02607059 | Epidemiologic Registry PETHEMA LMA 2015 | unknown | — | 500 | PETHEMA FoundationOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04806659 | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia | unknown | Phase 1 | 41 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04692948 | TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia | unknown | N/A | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT04747002 | Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients. | unknown | Phase 2 | 100 | Osaka UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04766840 | Donor-derived CAR-T Cells in the Treatment of AML Patients | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03662724 | Venetoclax Registry(VENreg) | unknown | — | 100 | Hannover Medical SchoolOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03096496 | Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy | unknown | — | 161 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04709731 | Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia(CarPAs) | unknown | Phase 2 | 50 | Associazione Italiana Pazienti Leucemia Mieloide CronicaOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04708444 | Prognostic Value of CD318 in AML at Assiut University Hospital. | unknown | — | 100 | Shimaa Arafa IbrahimOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT03955848 | INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS(NKAML) | unknown | N/A | 80 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04254640 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03135054 | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT02172365 | Allogeneic SCT for CML, TKI Failure After TKI Failure | unknown | — | 350 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT01064570 | AIDA 2000 Guidelines | unknown | Phase 2 | 600 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 3, 2021source: clinicaltrials